Latest Nasdaq News

JPMorgan US 100Q Equity Premium Income ETF lifted operating profit to A$15.678 million as net assets grew to A$106.991 million. The fund is now preparing to move its underlying investment from a Nasdaq-listed ETF to a London-listed UCITS vehicle, with total management fees and costs unchanged at 0.40% a year.

Telix’s Pixclara has become the first FDA-approved FET-PET imaging drug for glioma, opening a new US diagnostic pathway for adults and children. The approval is commercially significant, but pricing, reimbursement and launch timing remain undisclosed.

Resolution Minerals has finished its largest-ever exploration program at the Horse Heaven project in Idaho, drilling 42 diamond holes across 12,236 metres. The work sets up a substantial run of gold, tungsten and multi-element assay results, but the completed program has not yet produced new assay data in this announcement.

Immutep has narrowed eftilagimod alfa’s potential registration pathway to PD-L1-negative head and neck cancer and neoadjuvant soft tissue sarcoma after identifying product differences between manufacturing scales used in earlier studies and TACTI-004. A new 200 L manufacturing run is planned, but replacement trials are not targeted to start until the second half of 2027 and remain subject to regulatory, funding and partnering decisions.

Elevra Lithium is positioning its Québec operations for a near-doubling in spodumene concentrate capacity, while guiding to modest production growth and sharply higher capital spending in FY27. The three-stage North American Lithium expansion is targeting 373,000 tonnes per year for an estimated US$271 million.

JPMorgan Asset Management has announced estimated September 2026 cash distributions for six of its equity premium income ETFs, with payments scheduled for mid-October.

Immuron Limited has inked an exclusive US distribution deal for PROIBS®, a European-certified medical device targeting abdominal discomfort, marking a key step in its digestive health portfolio growth.

Cleo Diagnostics has received its first commercial batch of ovarian cancer test kits from Bio-Techne, marking the start of analytical validation critical for its FDA submission planned in early 2027.

Telix Pharmaceuticals has completed enrollment in its pivotal Phase 3 BiPASS trial for prostate cancer imaging and aligned with the FDA on a pathway that could expand U.S. patient access and reimbursement for its 68Ga-PSMA-PET agents.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

Alterity Therapeutics has arranged an underwriting deal for up to 8.4 million ATHO options, potentially raising A$4.2 million to A$7.96 million ahead of their expiry. The funds aim to support the upcoming Phase 3 trial for ATH434 in Multiple System Atrophy and bolster working capital.

Tamboran Resources is poised to deliver first gas sales from its Beetaloo Basin pilot project, backed by a robust balance sheet and strategic partnerships aiming to slash drilling costs.